Caleres (CAL)
(Delayed Data from NYSE)
$32.25 USD
+0.49 (1.54%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $32.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.25 USD
+0.49 (1.54%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $32.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Zacks News
Should Value Investors Pick Caleres, Inc. (CAL) Stock?
by Zacks Equity Research
Is Caleres, Inc. (CAL) a great pick from the value investor's perspective right now? Read on to know more.
Zacks.com highlights: Caleres, Archer Daniels Midland, WellCare Health Plans, Comstock Resources and United States Steel
by Zacks Equity Research
Zacks.com highlights: Caleres, Archer Daniels Midland, WellCare Health Plans, Comstock Resources and United States Steel
5 Stocks in the Spotlight on Recent Broker Rating Upgrades
by Zacks Equity Research
It is in the best interest of investors to pay heed to broker advice as they aim to generate maximum returns from their portfolio.
Company News For Mar 15, 2018
by Zacks Equity Research
Companies In The News are: SIG,MDB,PUK,CAL
Why Earnings Season Could Be Great for Caleres (CAL)
by Zacks Equity Research
Caleres (CAL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
IMAX to Expand Latin American Base Through Supercines Deal
by Zacks Equity Research
IMAX continues to make efforts for global expansion. The company inks a sales deal with Supercines to widen base across Latin America.
Is Caleres (CAL) a Great Stock for Value Investors?
by Zacks Equity Research
Is Caleres (CAL) a great pick from the value investor's perspective right now? Read on to know more.
IMAX Q3 Earnings & Revenues Surpass Estimates, Stock Jumps
by Zacks Equity Research
IMAX shines in Q3 although the movie industry remained downcast. The company's revenues record a 14.2% year-over-year rise. Services revenues climb 33.9%, Network Business revenues grow 16.8%.
Viacom (VIAB) Hits a 52-Week Low Due to Multiple Headwinds
by Zacks Equity Research
Viacom (VIAB) slumps to a 52-week low due to reduction in domestic advertising revenues, high debt level and tough competition in the cable television industry.
Zacks.com featured highlights include Greenbrier, Preferred Apartment Communities, Caleres, American Equity Investment Life and Itron
by Zacks Equity Research
Zacks.com featured highlights include Greenbrier, Preferred Apartment Communities, Caleres, American Equity Investment Life and Itron
Tap These 5 Value Stocks With Exciting EV/EBITDA Ratios
by Zacks Equity Research
We have screened value stocks based on EV/EBITDA ratio that offers a clearer image of a company's valuation and earnings potential.
Caleres (CAL) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Caleres, Inc. (CAL) was a big mover last session, as the company saw its shares rise over 6% on the day.
Top Ranked Growth Stocks to Buy for July 24th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 24th:
Top Ranked Growth Stocks to Buy for July 14th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 14th:
Caleres (CAL) Soars: Stock Adds 9.1% in Session
by Zacks Equity Research
The Caleres (CAL) stock price rose 9.1% on the day probably on the back of its better-than-expected first quarter 2017 results.
New Strong Sell Stocks for April 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
What Makes Caleres (CAL) a Strong Sell?
by Zacks Equity Research
Caleres (CAL) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
Duluth Holdings (DLTH) to Post Q4 Earnings: What to Expect?
by Zacks Equity Research
Duluth Holdings Inc. (DLTH) is scheduled to report fourth-quarter 2016 results on Mar 21, after the closing bell.
WPP's Ogilvy Forms Strategic Partnership with Demandbase
by Zacks Equity Research
Ogilvy CommonHealth Worldwide, one of the operating units of WPP plc (WPPGY), recently formed a strategic technology partnership with Demandbase.
Why Caleres (CAL) Might Surprise This Earnings Season
by Zacks Equity Research
Caleres (CAL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Caleres Be a Top Choice for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Caleres (CAL) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Caleres, Inc. (CAL) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Caleres (CAL) Stock Might be a Great Pick
by Zacks Equity Research
Caleres (CAL) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
Duluth Holdings (DLTH) Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Duluth Holdings Inc. (DLTH) is scheduled to report third-quarter 2016 results on Dec 8, after the closing bell.
Anatomy of Success: Short-Term (BWS)
by Kevin Matras
See how to apply the Zacks Rank to find stocks that will outperform over the next 1-3 months.